5F-PB-22

arrhythmia, coronary artery disease, cardiomyopathy

Full CB1 receptor agonism by 5F-PB-22 induces tachycardia and autonomic destabilization. Class-level data from synthetic cannabinoid presentations document myocardial infarction, ischemic stroke, and arrhythmia. Pre-existing cardiovascular disease amplifies these risks. Multiple fatalities involving 5F-PB-22 have been published, with cardiac involvement implicated.

epilepsy, seizure disorders

Generalized tonic-clonic seizures are reported in synthetic cannabinoid clinical presentations. Pre-existing seizure disorders may lower the threshold for this adverse event. No 5F-PB-22-specific seizure data exist; this contraindication is extrapolated from the synthetic cannabinoid class.

schizophrenia, schizoaffective disorder, family history of psychosis

Full CB1 receptor agonism without the antipsychotic modulation provided by CBD in cannabis substantially increases psychotomimetic risk. Class-level data identify first-episode psychosis, paranoia, and acute agitation as recognized psychiatric complications of synthetic cannabinoid use. The extreme CB1 potency of 5F-PB-22 (26-fold greater than JWH-018) may compress the dose range at which psychotomimetic effects emerge. Individuals with psychotic disorders or family history of psychosis face elevated risk.

hepatic impairment, liver disease

The primary metabolic pathway for 5F-PB-22 is CES1-catalyzed ester hydrolysis, which occurs predominantly in the liver. Hepatic impairment could reduce the rate of parent compound degradation, prolonging exposure to the high-potency full CB1 agonist and potentially increasing the risk and duration of adverse effects. This contraindication is inferred from the compound's metabolic pathway, not from clinical observation.

renal impairment, chronic kidney disease

Acute kidney injury is documented in the class-level synthetic cannabinoid adverse event profile. Pre-existing renal impairment may increase susceptibility to this complication. No 5F-PB-22-specific renal toxicity data exist; this contraindication is extrapolated from the synthetic cannabinoid class.

pregnancy

5F-PB-22 at biologically relevant concentrations (≤1 μM) approximately doubled neuronal differentiation and neurite outgrowth via a CB1R-dependent mechanism in vitro. Endocannabinoid signaling plays a critical role in guiding axonal pathfinding, synaptogenesis, and neuronal migration during prenatal and early postnatal development. Full agonist disruption of this system poses theoretical developmental risk. No in vivo developmental toxicity studies have been published.

concurrent alcohol consumption

Three independent lines of evidence establish ethanol co-use as high-risk: (1) pharmacodynamic additive CNS depression, (2) pharmacokinetic transesterification producing a novel bioactive ethyl ester metabolite confirmed in postmortem blood at 0.4 μg/L, and (3) multiple published fatalities involving ethanol co-detection (UK fatality with BAC 311 mg/100mL; German fatality with ethanol co-detected). This is the only contraindication with substance-specific evidence rather than pure class extrapolation.